TRDA Insider Trading

Insider Ownership Percentage: 7.59%
Insider Buying (Last 12 Months): $31,955.04
Insider Selling (Last 12 Months): $1,294,741.67

Entrada Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Entrada Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$500k$0$500kTotal Insider BuyingTotal Insider Selling

Entrada Therapeutics Share Price & Price History

Current Price: $8.13
Price Change: Price Increase of +0.27 (3.44%)
As of 04/17/2025 05:00 PM ET

This chart shows the closing price history over time for TRDA up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMarApr$8.13Closing price on 04/20/25:

SEC Filings (Institutional Ownership Changes) for Entrada Therapeutics (NASDAQ:TRDA)

86.39% of Entrada Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at TRDA by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$109kbought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$10M-$5M$0$5M$10MTotal InflowsTotal Outflows
Entrada Therapeutics logo
Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Read More on Entrada Therapeutics

Today's Range

Now: $8.13
Low: $7.79
High: $8.38

50 Day Range

MA: $10.30
Low: $7.55
High: $13.44

52 Week Range

Now: $8.13
Low: $7.10
High: $21.79

Volume

158,883 shs

Average Volume

124,051 shs

Market Capitalization

$305.65 million

P/E Ratio

5.11

Dividend Yield

N/A

Beta

0.04

Who are the company insiders with the largest holdings of Entrada Therapeutics?

Entrada Therapeutics' top insider shareholders include:
  1. Bioventures 2018 LP Mpm (Major Shareholder)
  2. Dipal Doshi (CEO)
  3. Natarajan Sethuraman (Insider)
  4. Nathan J Dowden (COO)
  5. Kory James Wentworth (CFO)
  6. Peter S Kim (Director)
  7. Nerissa Kreher (Insider)
Learn More about top insider investors at Entrada Therapeutics.

Who are the major institutional investors of Entrada Therapeutics?

Entrada Therapeutics' top institutional shareholders include:
  1. Harbor Capital Advisors Inc. — 0.04%
Learn More about top institutional investors of Entrada Therapeutics stock.

Which institutional investors are buying Entrada Therapeutics stock?

In the previous quarter, TRDA stock was purchased by institutional investors including:
  1. Harbor Capital Advisors Inc.